Regeneron Pharmaceuticals Inc.’s (REGN) blockbuster eye drug, EYLEA, has received European approval for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV). Myopic CNV is an eye disease associated with high degrees of myopia (near-sightedness) and frequently affects people of working age.